Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

2025年6月22日EADV (欧洲皮肤病与性病学会）理事会成员、葡萄牙CUF集团Descobertas医院皮肤中心的Pedro Miguel Mendes Bastos教授应邀访问四川大学华西医院皮肤科，围绕特应性皮炎（Atopic ...

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...

Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...